Finoriq research workspace
Compass Therapeutics, Inc. (CMPX) SEC Filings & Filing Highlights
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops. Review CMPX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
- Company
- Compass Therapeutics, Inc. (CMPX)
- Ticker
- CMPX
- Market Cap
- $366.5M
- Latest Price
- $2.035
- Industry
- Biotech & Pharma
Compass Therapeutics, Inc. (CMPX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Compass Therapeutics, Inc. (CMPX).
| Event | Form | Date |
|---|---|---|
| On July 1, 2026, Compass Therapeutics, Inc. updated its corporate presentation to reflect its m...On July 1, 2026, Compass Therapeutics, Inc. updated its corporate presentation to reflect its most recent corporate updates, including data... | 8-K7.01 | 2026-07-01 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-06-23 |
| Broker Non-votesOn June 10, 2026 Compass Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. The final results for each of the matt... | 8-K5.07 | 2026-06-11 |
| Compass Therapeutics, Inc.: Earnings or resultsOn May 5, 2026, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026. A copy... | 8-K2.02 | 2026-05-05 |
| Tovecimig results in Phase 2/3 Study in the Second Line Setting for Patients with BTCTovecimig results in Phase 2/3 Study in the Second Line Setting for Patients with BTC | 8-K8.01 | 2026-04-27 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.